                         SEQUENCE LISTING

<110>  Yeda Research and Development Co. Ltd.
       YARDEN, Yosef
       NORONHA, Ashish
 
<120>  COMBINATION THERAPY FOR THE TREATMENT OF CANCER

<130>  92290

<150>  US 63/214,371
<151>  2021-06-24

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  complementarity determining region (CDR)

<400>  1

Gln Asn Val Asp Thr Asn 
1               5       


<210>  2
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  complementarity determining region (CDR)

<400>  2

Ser Ala Phe 
1           


<210>  3
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  complementarity determining region (CDR)

<400>  3

Gln Gln Tyr Asn Asn Tyr Pro Tyr Thr 
1               5                   


<210>  4
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  complementarity determining region (CDR)

<400>  4

Gly Phe Thr Phe Ser Thr Tyr Gly 
1               5               


<210>  5
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  complementarity determining region (CDR)

<400>  5

Ile Asn Gly Asn Gly Gly Ser Ala 
1               5               


<210>  6
<211>  15
<212>  PRT
<213>  Artificial sequence

<220>
<223>  complementarity determining region (CDR)

<400>  6

Val Arg Glu Arg Asp Tyr Tyr Gly Asn Ser Arg Tyr Phe Asp Val 
1               5                   10                  15  


<210>  7
<211>  322
<212>  DNA
<213>  Artificial sequence

<220>
<223>  exemplary nucleic acid sequence of the light chain of antibody 
       directed to AXL

<400>  7
gacattgtga tgacccagtc tcaaaaattc atgtccacat cagtgggaga cagggtcagc       60

gtcacctgca aggccagtca gaatgtggat actaatgtgg cctggtatca acagaaacca      120

ggacaatctc ctaaaccact gattttctcg gcattcctcc ggtacagtgg agtccctgat      180

cgcttcacag gcagtggatc tgggacagat ttcagtctca ccgtcagcaa tgtgcagtct      240

gaagacttgg cagagtattt ctgtcagcaa tataacaatt atccgtacac gttcggaggg      300

gggaccaagc tggaaatgaa ac                                               322


<210>  8
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  exemplary amino acid sequence of the light chain of antibody 
       directed to AXL

<400>  8

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Pro Leu Ile 
        35                  40                  45              


Phe Ser Ala Phe Leu Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Val Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Asn Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys 
            100                 105         


<210>  9
<211>  366
<212>  DNA
<213>  Artificial sequence

<220>
<223>  exemplary nucleic acid sequence of the heavy chain of antibody 
       directed to AXL

<400>  9
gaggaacagt tggtggagtc tgggggaggc ttagtgcagc ctggagggtc cctgaaactc       60

tcctgtgcag cctctggatt cactttcagt acctatggca tgtcttgggt tcgccagact      120

ccagacaaga ggctggagtt ggtcgcaacc ataaatggta atggtggtag tgcctattat      180

ccagacagtg tgaagggccg attcaccata tccagagaca acggcaagaa caccctgtac      240

ctgcaaatga gcagtctgaa gtctgaggac acagccatgt attactgtgt aagagagagg      300

gattattacg gtaatagtcg ctacttcgat gtctggggcg cagggaccgc ggtcaccgtc      360

tcctca                                                                 366


<210>  10
<211>  120
<212>  PRT
<213>  Artificial sequence

<220>
<223>  exemplary amino acid sequence of the heavy chain of antibody 
       directed to AXL

<400>  10

Glu Glu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Leu Val 
        35                  40                  45              


Ala Thr Ile Asn Gly Asn Gly Gly Ser Ala Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Val Arg Glu Arg Asp Tyr Tyr Gly Asn Ser Arg Tyr Phe Asp Val Trp 
            100                 105                 110         


Gly Ala Gly Thr Ala Val Thr Val 
        115                 120 


